
Story by Vandana Singh
Medicus Pharma Ltd. MDCX secured on Wednesday an exclusive, sublicensable global license from Pfizer Inc. PFE to develop, manufacture, and commercialize PF-08046031 (CD228V), an early clinical-stage antibody-drug conjugate targeting melanotransferrin.
Continue reading Medicus Pharma Inks Global Licensing Deal With Pfizer Worth Over $1 Billion










































































